SCHEMBL27852001

SCHEMBL27852001

CC(=O)Nc1nc2c(s1)C(O)=C(C(=O)c1ccc(C(C)C(C)(C)OC(N)=O)nc1)CCC2

nearest known ligand 0.34

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.34
TP53 P04637 2/20 0.34
RAB9A P51151 2/20 0.34
ALDH1A1 P00352 2/20 0.34
NPC1 O15118 1/20 0.34
POLB P06746 1/20 0.34
LMNA P02545 3/20 0.33
MAPT P10636 2/20 0.33
GAA P10253 1/20 0.33
HPGD P15428 1/20 0.33
CFTR P13569 5/20 0.32
PIK3CG P48736 8/20 0.32
PIK3CA P42336 4/20 0.32
PIK3CD O00329 3/20 0.32
PIK3CB P42338 3/20 0.32
DYRK1A Q13627 1/20 0.32
PIK3C3 Q8NEB9 1/20 0.31
PI4KB Q9UBF8 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27869088 0.91 CFTR (0.32) SMN1; SMN2TP53RAB9AALDH1A1NPC1
SCHEMBL27852003 0.83 MAPT (0.34) SMN1; SMN2TP53RAB9AALDH1A1NPC1
SCHEMBL1118042 0.82 PIK3CG (0.38) SMN1; SMN2TP53RAB9AALDH1A1NPC1
SCHEMBL1782768 0.78 HCAR3 (0.43) SMN1; SMN2TP53RAB9AALDH1A1NPC1
SCHEMBL27857568 0.77 PI4KA (0.33) SMN1; SMN2RAB9ANPC1LMNAMAPT
SCHEMBL1770958 0.76 ABL1 (0.34) SMN1; SMN2TP53RAB9AALDH1A1NPC1
SCHEMBL691255 0.76 ALDH1A1 (0.39) SMN1; SMN2TP53RAB9AALDH1A1NPC1
SCHEMBL13690398 0.76 PIK3CA (0.43) LMNAMAPTGAAHPGDPIK3CG
SCHEMBL1781491 0.75 PIK3CG (0.42) SMN1; SMN2TP53RAB9AALDH1A1NPC1
SCHEMBL1783767 0.75 PIK3CG (0.39) LMNAMAPTGAAHPGDPIK3CG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-102459282-A Thia-triaza-cyclopentazulenes as PI 3-kinase inhibitors for the treatment of cancer BOEHRINGER INGELHEIM INT 2012-05-16 CN disclosed